SCHEMBL22761996

SCHEMBL22761996

BrC[C@H]1CC[C@@H](OCc2ccccc2)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OPRM1 P35372 2/20 0.49
OPRL1 P41146 2/20 0.49
DPP4 P27487 1/20 0.49
SIGMAR1 Q99720 2/20 0.47
CARM1 Q86X55 2/20 0.47
PRMT6 Q96LA8 2/20 0.47
TMEM97 Q5BJF2 1/20 0.47
PRMT8 Q9NR22 1/20 0.47
HRH3 Q9Y5N1 1/20 0.47
CTSL P07711 1/20 0.46
CTSB P07858 1/20 0.46
CTSK P43235 1/20 0.46
EPHX2 P34913 1/20 0.42
SLC6A2 P23975 1/20 0.40
HTR2A P28223 1/20 0.40
HTR2C P28335 1/20 0.40
SLC6A4 P31645 1/20 0.40
HTR7 P34969 1/20 0.40
HTR2B P41595 1/20 0.40
HTR3A P46098 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17103421 1.00 OPRM1 (0.49) OPRM1OPRL1DPP4SIGMAR1CARM1
SCHEMBL17103420 1.00 OPRM1 (0.49) OPRM1OPRL1DPP4SIGMAR1CARM1
SCHEMBL6469380 0.87 OPRM1 (0.59) OPRM1OPRL1DPP4SIGMAR1CARM1
SCHEMBL5518818 0.82 DPP4 (0.56) OPRM1OPRL1DPP4SIGMAR1CARM1
SCHEMBL22762091 0.82 OPRM1 (0.49) OPRM1OPRL1DPP4SIGMAR1CARM1
SCHEMBL17103669 0.82 OPRM1 (0.49) OPRM1OPRL1DPP4SIGMAR1CARM1
SCHEMBL10327058 0.82 OPRM1 (0.53) OPRM1OPRL1DPP4SIGMAR1CARM1
SCHEMBL5518823 0.82 DPP4 (0.56) OPRM1OPRL1DPP4SIGMAR1CARM1
SCHEMBL17103670 0.82 OPRM1 (0.49) OPRM1OPRL1DPP4SIGMAR1CARM1
SCHEMBL6108529 0.81 OPRM1 (0.54) OPRM1OPRL1DPP4SIGMAR1CARM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230234978-A1 NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF Atrium Therapeutics, Inc. 2023-07-27 US disclosed
WO-2020247782-A1 NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF AVIDITY BIOSCIENCES, INC. (US) 2020-12-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230234978-A1 NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF POLM, POLN, POLI OPRM1 1506/4885OPRL1 779/4885DPP4 2804/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.